학술논문
SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies.
Document Type
Author
Moyo-Gwete T; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.; Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.; Madzivhandila M; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.; Makhado Z; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.; Ayres F; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.; Mhlanga D; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.; Oosthuysen B; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.; Lambson BE; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.; Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.; Kgagudi P; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.; Tegally H; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Department of Laboratory Medicine & Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.; Iranzadeh A; Institute of Infectious Disease and Molecular Medicine, Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town, South Africa.; Doolabh D; Institute of Infectious Disease and Molecular Medicine, Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town, South Africa.; Tyers L; Institute of Infectious Disease and Molecular Medicine, Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town, South Africa.; Chinhoyi LR; Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Cape Town, South Africa.; Division of Cardiology, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.; Hatter Institute for Cardiovascular Research in Africa, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.; Mennen M; Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Cape Town, South Africa.; Division of Cardiology, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.; Hatter Institute for Cardiovascular Research in Africa, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.; Skelem S; Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Cape Town, South Africa.; Division of Cardiology, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.; Hatter Institute for Cardiovascular Research in Africa, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.; Marais G; Institute of Infectious Disease and Molecular Medicine, Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town, South Africa.; National Health Laboratory Services, Groote Schuur Hospital, Cape Town, South Africa.; Wibmer CK; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.; Bhiman JN; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.; Department of Virology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.; Ueckermann V; Division for Infectious Diseases, Department of Internal Medicine, Steve Biko Academic Hospital and University of Pretoria, Pretoria, South Africa.; Rossouw T; Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.; Boswell M; Division for Infectious Diseases, Department of Internal Medicine, Steve Biko Academic Hospital and University of Pretoria, Pretoria, South Africa.; de Oliveira T; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Department of Laboratory Medicine & Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.; Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.; Department of Global Health, University of Washington, Seattle, USA.; Williamson C; Institute of Infectious Disease and Molecular Medicine, Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town, South Africa.; Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Cape Town, South Africa.; National Health Laboratory Services, Groote Schuur Hospital, Cape Town, South Africa.; Burgers WA; Institute of Infectious Disease and Molecular Medicine, Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town, South Africa.; Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Cape Town, South Africa.; Ntusi N; Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Cape Town, South Africa.; Division of Cardiology, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.; Hatter Institute for Cardiovascular Research in Africa, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.; Morris L; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.; Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.; Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.; Moore PL; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.; Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.; Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Source
Country of Publication: United States NLM ID: 101680187 Publication Model: Electronic Cited Medium: Internet NLM ISO Abbreviation: bioRxiv Subsets: PubMed not MEDLINE
Subject
Language
English
Abstract
Neutralization escape by SARS-CoV-2 variants, as has been observed in the 501Y.V2 (B.1.351) variant, has impacted the efficacy of first generation COVID-19 vaccines. Here, the antibody response to the 501Y.V2 variant was examined in a cohort of patients hospitalized with COVID-19 in early 2021 - when over 90% of infections in South Africa were attributed to 501Y.V2. Robust binding and neutralizing antibody titers to the 501Y.V2 variant were detected and these binding antibodies showed high levels of cross-reactivity for the original variant, from the first wave. In contrast to an earlier study where sera from individuals infected with the original variant showed dramatically reduced potency against 501Y.V2, sera from 501Y.V2-infected patients maintained good cross-reactivity against viruses from the first wave. Furthermore, sera from 501Y.V2-infected patients also neutralized the 501Y.V3 (P.1) variant first described in Brazil, and now circulating globally. Collectively these data suggest that the antibody response in patients infected with 501Y.V2 has a broad specificity and that vaccines designed with the 501Y.V2 sequence may elicit more cross-reactive responses.